MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Pfizer

Отворен

СекторЗдравеопазване

22.87 0.48

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

22.5

Максимум

22.85

Ключови измерители

By Trading Economics

Приходи

-4.1B

411M

Продажби

63M

18B

P/E

Средно за сектора

15.631

57.333

EPS

0.63

Дивидентна доходност

7.8

Марж на печалбата

2.314

Служители

81,000

EBITDA

-4.3B

2.5B

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+22.04% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

7.80%

2.63%

Следващи печалби

29.04.2025 г.

Следваща дата на дивидент

13.06.2025 г.

Следваща дата на екс-дивидент

9.05.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-26B

126B

Предишно отваряне

22.39

Предишно затваряне

22.87

Техническа оценка

By Trading Central

Увереност

Strong Bullish Evidence

Pfizer Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

14.04.2025 г., 11:09 ч. UTC

Значими двигатели на пазара

Pfizer Shares Slip After Company Scraps Weight-Loss Pill

9.04.2025 г., 18:18 ч. UTC

Значими двигатели на пазара

Pharma Shares Reverse Losses After Tariff Pause

9.04.2025 г., 09:39 ч. UTC

Значими двигатели на пазара

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

19.03.2025 г., 07:34 ч. UTC

Придобивния, сливания и поглъщания

Pfizer Sells Remaining 7.3% Haleon Shareholding for $3.25 Billion

18.03.2025 г., 17:26 ч. UTC

Придобивния, сливания и поглъщания

Pfizer to Dispose of Remaining Shareholding in Haleon

14.04.2025 г., 14:36 ч. UTC

Топ новини

Pfizer Halts Development of Weight-Loss Pill -- Update

14.04.2025 г., 14:14 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Viking Seen as Potential Ticket To Get Pfizer Back Into Obesity Game -- Market Talk

14.04.2025 г., 10:45 ч. UTC

Топ новини

Pfizer Halts Development of Weight-Loss Pill -- WSJ

8.04.2025 г., 21:26 ч. UTC

Печалби

Pfizer Stock's Fall to '97 Level Lifts Yield Near 8%. Dividend Looks Safe. -- Barrons.com

26.03.2025 г., 22:29 ч. UTC

Топ новини

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- 2nd Update

26.03.2025 г., 19:19 ч. UTC

Топ новини

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- Update

26.03.2025 г., 17:39 ч. UTC

Топ новини

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- WSJ

18.03.2025 г., 16:58 ч. UTC

Придобивния, сливания и поглъщания

Haleon Intends to Cancel Purchased Ordinary Shares

18.03.2025 г., 16:57 ч. UTC

Придобивния, сливания и поглъщания

Citigroup: Off-Market Transaction Will Close at Same Time as or Following Settlement of Offering

18.03.2025 г., 16:56 ч. UTC

Придобивния, сливания и поглъщания

Citigroup: Off-Market Purchase Worth Approx GBP170M in Ordinary Shares

18.03.2025 г., 16:56 ч. UTC

Придобивния, сливания и поглъщания

Citigroup: Haleon Agreed to Carry out Off-Market Purchase From Pfizer

18.03.2025 г., 16:52 ч. UTC

Придобивния, сливания и поглъщания

Haleon Takes Note of Announcement

18.03.2025 г., 16:50 ч. UTC

Придобивния, сливания и поглъщания

Citigroup: Haleon Won't Receive Any Net Proceeds From Offering

18.03.2025 г., 16:50 ч. UTC

Придобивния, сливания и поглъщания

Citigroup: This Is Subject to Customary Closing Conditions

18.03.2025 г., 16:50 ч. UTC

Придобивния, сливания и поглъщания

Citigroup: Pfizer Will Receive All of Net Proceeds From Offering

18.03.2025 г., 16:49 ч. UTC

Придобивния, сливания и поглъщания

Citigroup: Bookbuilding Period May Close at Any Time on Short Notice

18.03.2025 г., 16:49 ч. UTC

Придобивния, сливания и поглъщания

Citigroup: Bookbuilding Period Will Commence Immediately

18.03.2025 г., 16:49 ч. UTC

Придобивния, сливания и поглъщания

Citigroup: Price Per Sale Share to Be Determined Through Accelerated Bookbuilding Process

18.03.2025 г., 16:48 ч. UTC

Придобивния, сливания и поглъщания

Citigroup: Pfizer Intends to Sell Ordinary Shares to Institutional Investors

18.03.2025 г., 16:47 ч. UTC

Придобивния, сливания и поглъщания

Citigroup:: Amount Is Pfizer's Entire Residual Shareholding in Haleon

18.03.2025 г., 16:47 ч. UTC

Придобивния, сливания и поглъщания

Citigroup: This Represents Approx 7.3% Stake in Haleon

18.03.2025 г., 16:46 ч. UTC

Придобивния, сливания и поглъщания

Citigroup: Pfizer Intends to Sell Approx 662M Ordinary Shares in Haleon

17.03.2025 г., 09:00 ч. UTC

Топ новини

Pfizer Has a New Playbook for Reviving Sales -- And It's Starting to Pay Off -- WSJ

28.02.2025 г., 12:00 ч. UTC

Топ новини

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

14.02.2025 г., 11:38 ч. UTC

Топ новини
Печалби

Moderna's Results Reaffirm a Grim Picture for Vaccine Maker -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Pfizer Прогноза

Ценова цел

By TipRanks

22.04% нагоре

12-месечна прогноза

Среден 27.8 USD  22.04%

Висок 32 USD

Нисък 23 USD

Според 17 анализатори от Wall Street, предложили 12-месечна ценова цел за Pfizer през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

17 ratings

5

Купи

12

Задържане

0

Продай

Техническа оценка

By Trading Central

22.12 / 23.055Подкрепа & съпротива

Краткосрочен план

Strong Bullish Evidence

Средносрочен план

Very Strong Bearish Evidence

Дългосрочен план

Bearish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.